Anna Kanerva

6.8k total citations
125 papers, 4.7k citations indexed

About

Anna Kanerva is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Anna Kanerva has authored 125 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Genetics, 93 papers in Oncology and 69 papers in Molecular Biology. Recurrent topics in Anna Kanerva's work include Virus-based gene therapy research (115 papers), CAR-T cell therapy research (90 papers) and Viral Infectious Diseases and Gene Expression in Insects (43 papers). Anna Kanerva is often cited by papers focused on Virus-based gene therapy research (115 papers), CAR-T cell therapy research (90 papers) and Viral Infectious Diseases and Gene Expression in Insects (43 papers). Anna Kanerva collaborates with scholars based in Finland, United States and Germany. Anna Kanerva's co-authors include Akseli Hemminki, David T. Curiel, Gerd Bauerschmitz, Vincenzo Cerullo, Ronald D. Alvarez, Tanja Hakkarainen, Merja Särkioja, Riikka Havunen, Lotta Kangasniemi and Renée A. Desmond and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Anna Kanerva

120 papers receiving 4.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Kanerva Finland	39	3.8k	3.1k	2.5k	995	695	125	4.7k
Matt Coffey United States	35	2.9k 0.8×	2.0k 0.6×	1.3k 0.5×	854 0.9×	643 0.9×	98	3.6k
Dirk M. Nettelbeck Germany	36	2.2k 0.6×	1.6k 0.5×	2.2k 0.9×	458 0.5×	549 0.8×	83	3.4k
Caroline J. Breitbach Canada	28	2.5k 0.7×	2.1k 0.7×	1.2k 0.5×	538 0.5×	1.1k 1.5×	51	3.5k
Terry Hermiston United States	33	2.7k 0.7×	1.5k 0.5×	2.4k 1.0×	489 0.5×	553 0.8×	61	3.8k
Steve H. Thorne United States	28	2.1k 0.6×	1.7k 0.6×	1.3k 0.5×	569 0.6×	833 1.2×	48	3.2k
Victor W. van Beusechem Netherlands	35	2.2k 0.6×	1.5k 0.5×	2.4k 1.0×	362 0.4×	396 0.6×	115	3.6k
Fiona Errington‐Mais United Kingdom	33	2.0k 0.5×	1.6k 0.5×	1.0k 0.4×	518 0.5×	877 1.3×	53	2.9k
Dechao Yu United States	27	1.5k 0.4×	1.2k 0.4×	1.4k 0.6×	428 0.4×	382 0.5×	57	2.7k
Britta Randlev United States	10	2.1k 0.6×	1.5k 0.5×	1.6k 0.6×	572 0.6×	139 0.2×	14	2.6k
Frederick J. Kohlhapp United States	14	1.1k 0.3×	1.3k 0.4×	919 0.4×	260 0.3×	814 1.2×	27	2.3k

Countries citing papers authored by Anna Kanerva

Since Specialization

Citations

This map shows the geographic impact of Anna Kanerva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kanerva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kanerva more than expected).

Fields of papers citing papers by Anna Kanerva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kanerva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kanerva. The network helps show where Anna Kanerva may publish in the future.

Co-authorship network of co-authors of Anna Kanerva

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Kanerva. A scholar is included among the top collaborators of Anna Kanerva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Kanerva. Anna Kanerva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pasanen, Annukka, et al.. (2025). PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study. International Journal of Gynecological Cancer. 35(9). 101934–101934. 2 indexed citations

Santos, João M., Matthew S. Block, Johanna Mäenpää, et al.. (2024). PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5562–5562.

Quixabeira, Dafne C.A., Sadia Zafar, João M. Santos, et al.. (2021). Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Frontiers in Immunology. 12. 674400–674400. 28 indexed citations

Zafar, Sadia, Dafne C.A. Quixabeira, João M. Santos, et al.. (2020). Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. Human Gene Therapy. 32(3-4). 192–202. 21 indexed citations

Cervera-Carrascón, Víctor, Mikko Siurala, João M. Santos, et al.. (2018). TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. OncoImmunology. 7(5). e1412902–e1412902. 90 indexed citations

Zheng, Guoqiao, et al.. (2018). Familial risks of ovarian cancer by age at diagnosis, proband type and histology. PLoS ONE. 13(10). e0205000–e0205000. 19 indexed citations

Liikanen, Ilkka, Siri Tähtinen, Kilian Guse, et al.. (2016). Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics. 15(9). 2259–2269. 30 indexed citations

Bramante, Simona, Anniina Koski, Ilkka Liikanen, et al.. (2015). Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. OncoImmunology. 5(2). e1078057–e1078057. 36 indexed citations

Kanerva, Anna, Petri Nokisalmi, Iulia Diaconu, et al.. (2013). Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research. 19(10). 2734–2744. 144 indexed citations

10.

Hirvinen, Mari, Raita Heiskanen, Minna Oksanen, et al.. (2013). Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. Journal of Translational Medicine. 11(1). 193–193. 15 indexed citations

11.

Koski, Anniina, Eerika Karli, Anja Kipar, et al.. (2013). Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism. PLoS ONE. 8(4). e60032–e60032. 8 indexed citations

12.

Pesonen, Sari, Iulia Diaconu, Lotta Kangasniemi, et al.. (2012). Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. Cancer Research. 72(7). 1621–1631. 107 indexed citations

13.

Liikanen, Ilkka, Vladia Monsurrò, Laura Ahtiainen, et al.. (2011). Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. Molecular Therapy. 19(10). 1858–1866. 39 indexed citations

14.

Kangasniemi, Lotta, Suvi Parviainen, Mika Jokinen, et al.. (2011). Effects of capsid‐modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer. International Journal of Cancer. 131(1). 253–263. 11 indexed citations

15.

Dias, João D., Ilkka Liikanen, Kilian Guse, et al.. (2010). Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. Clinical Cancer Research. 16(9). 2540–2549. 36 indexed citations

16.

Guse, Kilian, Marta Słoniecka, Ari Ristimäki, et al.. (2009). Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Therapy. 16(8). 1009–1020. 21 indexed citations

17.

Pesonen, Sari, Petri Nokisalmi, Ari Ristimäki, et al.. (2008). Treatment of cancer patients with capsid modified double controlled oncolytic adenovirus Ad5/3-Cox2L-D24. Cancer Research. 68. 2818–2818. 1 indexed citations

18.

Kanerva, Anna, Mari Raki, & Akseli Hemminki. (2007). Gene therapy of gynaecological diseases. Expert Opinion on Biological Therapy. 7(9). 1347–1361. 14 indexed citations

19.

Volk, Andrea L., Ángel A. Rivera, Anna Kanerva, et al.. (2003). Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism. Cancer Biology & Therapy. 2(5). 511–515. 59 indexed citations

20.

Hemminki, Akseli, Anna Kanerva, Eric J. Kremer, et al.. (2003). A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Molecular Therapy. 7(2). 163–173. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact